STAT+: Why the latest heart drug failures should make us all more skeptical of AI hype
Once again, a hot new technology that was supposed to speed up drug research has fallen flat.
In recent years, the promise of artificial intelligence (AI) and other new technologies to revolutionize healthcare has come under scrutiny. Two recent studies presented at the American Heart Association meeting serve as a stark reminder of the challenges faced by pharmaceutical researchers. Despite advancements in genetic understanding, a Novartis drug called pelacarsen failed to reduce the incidence of heart attacks and strokes, despite being expected to lower the blood substance lp(a).
Additionally, a Novo Nordisk study on an anti-inflammatory targeting the protein IL-6 also found no benefit. These failures should serve as a cautionary tale, urging us to approach claims of AI-driven healthcare breakthroughs with a healthy dose of skepticism.
Written by urgent.news from STAT News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
